Non- Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases
- PMID: 36836326
- PMCID: PMC9964096
- DOI: 10.3390/jof9020212
Non- Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases
Abstract
The incidence of invasive sino-pulmonary diseases due to non-Aspergillus hyaline molds is increasing due to an enlarging and evolving population of immunosuppressed hosts as well as improvements in the capabilities of molecular-based diagnostics. Herein, we review the following opportunistic pathogens known to cause sinopulmonary disease, the most common manifestation of hyalohyphomycosis: Fusarium spp., Scedosporium spp., Lomentospora prolificans, Scopulariopsis spp., Trichoderma spp., Acremonium spp., Paecilomyces variotii, Purpureocillium lilacinum, Rasamsonia argillacea species complex, Arthrographis kalrae, and Penicillium species. To facilitate an understanding of the epidemiology and clinical features of sino-pulmonary hyalohyphomycoses in the context of host immune impairment, we utilized a host-based approach encompassing the following underlying conditions: neutropenia, hematologic malignancy, hematopoietic and solid organ transplantation, chronic granulomatous disease, acquired immunodeficiency syndrome, cystic fibrosis, and healthy individuals who sustain burns, trauma, or iatrogenic exposures. We further summarize the pre-clinical and clinical data informing antifungal management for each pathogen and consider the role of adjunctive surgery and/or immunomodulatory treatments to optimize patient outcome.
Keywords: Acremonium; Arthrographis; Fusarium; Lomentospora prolificans; Paecilomyces; Rasamsonia; Scedosporium; Scopulariopsis; Trichoderma; hyaline molds.
Conflict of interest statement
T.J.W. has received grants for experimental and clinical antimicrobial pharmacology, therapeutics, and diagnostics to his institution from Amplyx, Astellas, Gilead, Lediant, Merck, Scynexis, Shionogi, T2 Biosystems, Viosera; and has served as a consultant to Astellas, Karyopharm, Leadiant, Partner Therapeutics, Scynexis, Shionogi, Statera, and T2 Biosystems.
References
-
- de Hoog G.S., Guarro J., Gene J., Ahmed S., Al-Hatmi A.M.S., Figueras M.J., Vitale R.G. Atlas of Clinical Fungi. 2023. [(accessed on 27 January 2023)]. Available online: https://www.clinicalfungi.org/
-
- O’Donnell K., Sutton D.A., Rinaldi M.G., Sarver B.A.J., Balajee S.A., Schroers H.J., Summerbell R.C., Robert V.A.R.G., Crous P.W., Zhang N., et al. Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J. Clin. Microbiol. 2010;48:3708–3718. doi: 10.1128/JCM.00989-10. - DOI - PMC - PubMed
-
- Tortorano A.M., Prigitano A., Esposto M.C., Arsic Arsenijevic V., Kolarovic J., Ivanovic D., Paripovic L., Klingspor L., Nordøy I., Hamal P., et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 2014;33:1623–1630. doi: 10.1007/s10096-014-2111-1. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
